Amgen Inc.
A biotechnology company that makes medicines for serious illnesses, including the bone-strengthening drug Prolia, the cholesterol-lowering injection Repatha, and the psoriasis treatment Otezla, sold to patients and doctors worldwide. It was founded in 1980 in Thousand Oaks, California, as Applied Molecular Genetics, a name later shortened to "Amgen." Its first CEO famously ran the company from a small trailer so scientists could use the office space, and early experiments included trying to extract oil from shale and accelerate chicken growth.
Granted 266.7K
Granted 102.9K · Sold 63.5K
Granted 45.5K · Sold 15.7K
Granted 40.4K
Granted 50.1K · Sold 33.9K
Granted 62.5K · Sold 35.0K
Granted 32.1K
Granted 2.2K
Granted 2.2K
Granted 2.2K
Granted 3.7K
Granted 2.2K
Granted 11.1K · Sold 2.0K
Granted 6.2K · Sold 2.4K
Granted 2.2K
Granted 2.2K
Granted 10.2K · Sold 11.4K
Granted 3.5K
Granted 3.4K
Granted 2.2K
Granted 3.2K · Sold 2.0K
Granted 2.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bradway Robert AChairman, CEO and President, Director · 24 transactions | — | 655.2K | 266.7K | — | — |
| Santos EstebanEVP, Operations · 25 transactions | +30% | 83.8K | 102.9K | — | 63.5K |
| Gordon MurdoEVP, Global Commercial Ops · 21 transactions | +15.6% | 51.2K | 45.5K | — | 15.7K |
| Griffith Peter H.EVP & CFO · 20 transactions | +56.8% | 50.1K | 40.4K | — | — |
| Reese David MEVP & Chief Technology Officer · 25 transactions | -21.9% | 42.3K | 50.1K | — | 33.9K |
| Graham Jonathan PEVP & Gen. Counsel & Sec. · 24 transactions | +0.4% | 39.7K | 62.5K | — | 35.0K |
| Bradner James E.EVP, Research and Development · 9 transactions | — | 30.0K | 32.1K | — | — |
| Eckert RobertDirector · 3 transactions | +16.9% | 26.3K | 2.2K | — | — |
| Jacks TylerDirector · 3 transactions | +23% | 18.3K | 2.2K | — | — |
| Kullman Ellen JamisonDirector · 3 transactions | +29.7% | 14.5K | 2.2K | — | — |
| Holley Charles MDirector · 11 transactions | +49.7% | 14.1K | 3.7K | — | — |
| Garland Greg C.Director · 3 transactions | +18.8% | 13.8K | 2.2K | — | — |
| Miller DerekSVP, Human Resources · 23 transactions | +64.8% | 12.4K | 11.1K | — | 2.0K |
| Khosla RachnaSVP, Business Development · 25 transactions | +10.7% | 8.4K | 6.2K | — | 2.4K |
| Druker BrianDirector · 3 transactions | +47.5% | 8.4K | 2.2K | — | — |
| Austin Wanda MDirector · 3 transactions | +37.6% | 8.0K | 2.2K | — | — |
| Grygiel Nancy A.SVP & CCO · 30 transactions | -43.6% | 7.4K | 10.2K | — | 11.4K |
| Ishrak OmarDirector · 11 transactions | +108.7% | 7.4K | 3.5K | — | — |
| Drake Michael VDirector · 11 transactions | +185.2% | 5.8K | 3.4K | — | — |
| Miles Amy EDirector · 3 transactions | +81.1% | 5.6K | 2.2K | — | — |
| Busch Matthew C.VP, Finance & CAO · 25 transactions | -5.5% | 4.3K | 3.2K | — | 2.0K |
| Klotman Mary E.Director · 3 transactions | — | 2.2K | 2.2K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -166.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.